Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype

MLA

B. Moulin, et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....867b5c82bc695efae3fd5e781460154b&authtype=sso&custid=ns315887.

APA

B. Moulin, Cécile Vigneau, Mathias Büchler, B. Hurault de Ligny, Y. Le Meur, Isabelle Etienne, E. Thervet, Marie-Anne Loriot, Gabriel Choukroun, E. Bailly, Anne-Elisabeth Heng, Antoine Thierry, Philippe Beaune, Charlotte Colosio, Nicolas Pallet, & C. Legendre. (2016). Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype.

Chicago

B. Moulin, Cécile Vigneau, Mathias Büchler, B. Hurault de Ligny, Y. Le Meur, Isabelle Etienne, E. Thervet, et al. 2016. “Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....867b5c82bc695efae3fd5e781460154b&authtype=sso&custid=ns315887.